Last reviewed · How we verify
NCT06658665: NPBC
Nomogram for Predicting Biliary Complication
trial in Liver Transplant Disorder in 900 participants. Not yet recruiting.
15 November 2024
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 900 |
| Start date | 1 November 2024 |
| Primary completion | 15 November 2024 |
| Estimated completion | 30 December 2024 |
Conditions studied
- Liver Transplant Disorder — all drugs for Liver Transplant Disorder →
Sponsor
Sun Yat-sen University
Who can join
18 and older, any sex, with Liver Transplant Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to develop a nomogram model to predict biliary complications within 90 days in adult patients after liver transplantation. The main questions it aims to answer are: Can the nomogram predict biliary complications within 90 days in adult patients after liver transplantation? What about the performance of the nomogram? Researchers will compare patients' preoperative variables, intraoperative factors, and postoperative outcomes to see what factors are associated with biliary complications.Subsequently, multivariable logistic regression analysis was conducted to evaluate the factors associated with biliary complications occurring within 90 days post-liver transplantation. Finally, a nomogram was developed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06658665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Transplant Disorder
Currently open trials in the same condition.
- NCT07315204 — Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion · recruiting
- NCT06455280 — A Study of SIPLIZUMAB in AILD and LT Patients · Phase 1 · recruiting
- NCT06577480 — Validity and Reliability of the Turkish Version of the Post-Liver Transplant Quality of Life Questionnaire · active not recruiting
- NCT06563570 — The Effect of Teleyoga in Liver Transplant Patients · NA · active not recruiting
- NCT05537948 — Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients · Phase 4 · active not recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06658665 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 26 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06658665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing